{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:36:07Z","timestamp":1787495767751,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":584,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1002\/rth2.12516","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T14:01:51Z","timestamp":1622210511000},"page":"e12516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Aspirin at 120: Retiring, recombining, or repurposing?"],"prefix":"10.1016","volume":"5","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12516_bb0010","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.phrs.2009.01.011","article-title":"Nonsteroidal antiinflammatory drugs: past, present and future","volume":"59","author":"Patrono","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1002\/rth2.12516_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low\u2010dose aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/rth2.12516_bb0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state\u2010of\u2010the\u2010art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/rth2.12516_bb0030","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"PEGASUS\u2010TIMI 54 steering committee and investigators. Long\u2010term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0035","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/rth2.12516_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/09537104.2018.1492105","article-title":"Aspirin, platelet inhibition and cancer prevention","volume":"29","author":"Patrignani","year":"2018","journal-title":"Platelets"},{"key":"10.1002\/rth2.12516_bb0050","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A critical appraisal of aspirin in secondary prevention: is less more?","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"10.1002\/rth2.12516_bb0055","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1538-7836.2009.03714.x","article-title":"Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy","volume":"8","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12516_bb0060","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1093\/eurheartj\/ehv551","article-title":"Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2","volume":"37","author":"Scavone","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12516_bb0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0070","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta\u2010analysis","volume":"142","author":"O\u2019Donoghue","year":"2020","journal-title":"Circulation"},{"issue":"37","key":"10.1002\/rth2.12516_bb0075","first-page":"267","volume":"2016","author":"Roffi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12516_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta\u2010analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/rth2.12516_bb0085","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0090","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","article-title":"Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: still sacrosanct or is reappraisal warranted?","volume":"142","author":"Jacobsen","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/rth2.12516_bb0095","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta\u2010analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"issue":"9872","key":"10.1002\/rth2.12516_bb0110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open\u2010label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"The Lancet"},{"key":"10.1002\/rth2.12516_bb0115","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"RE\u2010DUAL PCI steering committee investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0125","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta\u2010analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta\u2010analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1002\/rth2.12516_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta\u2010analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1002\/rth2.12516_bb0145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0150","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low\u2010dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2005.01701.x","article-title":"Co\u2010localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction","volume":"4","author":"Hoshiba","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12516_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis\u20102 Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT\u20102 study): a randomised controlled trial","volume":"360","author":"van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0165","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0170","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s11606-007-0233-1","article-title":"Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN\u2010RANGE study","volume":"22","author":"Parker","year":"2007","journal-title":"J Gen Intern Med"},{"key":"10.1002\/rth2.12516_bb0175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59\u20137939\u2013an oral, direct Factor Xa inhibitor\u2013after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/rth2.12516_bb0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS\u2010TIMI 46): a randomised, double\u2010blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20137939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/rth2.12516_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0200","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0205","article-title":"A controlled trial of rivaroxaban after transcatheter aortic\u2010valve replacement. Reply","volume":"383","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0210","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0215","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin\u2010receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0230","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high\u2010risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0240","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","article-title":"Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open\u2010label, phase 3 superiority trial","volume":"391","author":"Bath","year":"2018","journal-title":"Lancet"},{"issue":"41","key":"10.1002\/rth2.12516_bb0245","first-page":"255","article-title":"ESC guidelines on diabetes, pre\u2010diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"2020","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1002\/rth2.12516_bb0250","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0255","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti\u2010inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/rth2.12516_bb0260","first-page":"4399","article-title":"Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study","volume":"48","author":"Kune","year":"1988","journal-title":"Cancer Res"},{"key":"10.1002\/rth2.12516_bb0265","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase\u20102","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0270","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo\u2010oxygenase\u20102 inhibitors and traditional non\u2010steroidal anti\u2010inflammatory drugs increase the risk of atherothrombosis? Meta\u2010analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/rth2.12516_bb0275","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long\u2010term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1002\/rth2.12516_bb0280","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta\u2010analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/rth2.12516_bb0285","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12516_bb0290","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10\u2010year follow\u2010up and registry\u2010based 20\u2010year data in the CAPP2 study: a double\u2010blind, randomised, placebo\u2010controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0295","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate\u2010day, low\u2010dose aspirin and cancer risk: long\u2010term observational follow\u2010up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12516_bb0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long\u2010term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0305","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short\u2010term effects of daily aspirin on cancer incidence, mortality, and non\u2010vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-med-060319-120913","article-title":"Aspirin in the prevention of colorectal neoplasia","volume":"72","author":"Drew","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1002\/rth2.12516_bb0315","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0320","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins\u2010Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12516_bb0325","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S2468-1253(19)30289-4","article-title":"Aspirin as an adjuvant treatment for cancer: feasibility results from the Add\u2010Aspirin randomised trial","volume":"4","author":"Joharatnam\u2010Hogan","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1002\/rth2.12516_bb0330","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1186\/s13063-020-04674-8","article-title":"Effect of chemoprevention by low\u2010dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS\u2010Lynch): study protocol for a multicenter, double\u2010blind, placebo\u2010controlled randomized controlled trial","volume":"21","author":"Soualy","year":"2020","journal-title":"Trials"},{"key":"10.1002\/rth2.12516_bb0335","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102. ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/rth2.12516_bb0340","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1016\/S0002-9343(97)00208-8","article-title":"Variability in risk of gastrointestinal complications with different nonsteroidal anti\u2010inflammatory drugs","volume":"104","author":"Garcia Rodriguez","year":"1998","journal-title":"Am J Med"},{"key":"10.1002\/rth2.12516_bb0345","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non\u2010steroidal anti\u2010inflammatory drugs: meta\u2010analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0350","first-page":"1046","article-title":"Risks and benefits of antithrombotic therapy in polycythemia vera: a systematic review","volume":"4","author":"Laureano","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0355","first-page":"39","article-title":"Silent brain ischemia in thalassemia patients: breaking the silence","volume":"4","author":"Karimi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0360","first-page":"38","article-title":"Thromboembolism in thalassemia patients: is aspirin protective against brain ischemia over three years follow up in beta thalassemia patients?","volume":"4","author":"Karimi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1002\/rth2.12516_bb0365","first-page":"9","article-title":"Disantangling the mechanisms behind the thrombotic complications of COVID\u201019 patients: insights into platelet and endothelial activation","volume":"4","author":"Canzano","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12516_bb0370","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363840. Accessed February 19, 2021"},{"key":"10.1002\/rth2.12516_bb0375","unstructured":"https:\/\/www.pharmaceutical\u2010journal.com\/news\u2010and\u2010analysis\/news\/aspirin\u2010added\u2010to\u2010recovery\u2010covid\u201019\u2010trial\u2010mps\u2010told\/20208522.article. Accessed January 30, 2021"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0380","first-page":"28","article-title":"Aspirin antiplatelet effects are associated with body weight","volume":"4","author":"Mourikis","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0385","first-page":"34","article-title":"Systemic aspirin esterification in subjects with cardiovascular diseases: impact of body size","volume":"4","author":"Porro","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12516_bb0390","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double\u2010blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"key":"10.1002\/rth2.12516_bb0395","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpt.702","article-title":"On\u2010pump cardiac surgery enhances platelet renewal and impairs aspirin pharmacodynamics: effects of improved dosing regimens","volume":"102","author":"Cavalca","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0400","first-page":"10","article-title":"Postoperative dual antiplatelet therapy is infuenced by platelet regeneration","volume":"4","author":"Hoffmann","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0405","first-page":"1044","article-title":"Amelioration of the pathologic changes in the hepatocyte\u2010SpeciBRAFV600E mutated mice by administration of aspirin","volume":"4","author":"Tanaka","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12516_bb0410","first-page":"52","article-title":"Small\u2010molecule factor XIa inhibitor, BMS\u2010986177\/JNJ\u201070033093, prevents and treats arterial thrombosis in rabbits at doses that preserve hemostasis","volume":"4","author":"Wong","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"14","key":"10.1002\/rth2.12516_bb0415","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST\u2010segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1002\/rth2.12516_bb0420","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12516_bb0425","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/eurheartj\/ehaa800","article-title":"Aspirin monotherapy vs. DAPT after TAVI: is less more? Comment on the POPular TAVI trial","volume":"41","author":"Galiuto","year":"2020","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1002\/rth2.12516_bb0430","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic\u2010valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12516","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:22:31Z","timestamp":1762863751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922013851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2475037922013851"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12516","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin at 120: Retiring, recombining, or repurposing?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12516"}}